Erol

ERol Therapeutics is a biotechnology company focused on developing transformative therapies that target the Unfolded Protein Response (UPR) to treat diseases driven by proteostatic imbalance and cellular stress. The company was co-founded by Lasker Award winners Peter Walter and Kazutoshi Mori, the pioneering scientists who discovered the UPR and its role in endoplasmic reticulum (ER) biology. ERol leverages deep expertise in the ER stress pathway to develop small molecule modulators that can selectively restore cellular homeostasis. Its research programs primarily target neurodegenerative disorders, metabolic diseases, and oncology, where protein misfolding plays a critical role in pathogenesis. Headquartered in San Francisco, the company is backed by prominent life science investors, including The Column Group.